MAPT and Alzheimer disease: The measurement of levels of amyloid-β (Aβ42), total-tau (t-tau), and phospho-tau181 (p-tau) in cerebrospinal fluid (CSF) can support the differential diagnosis of AD, and support the prediction of those individuals with mild cognitive impairment (MCI) potentially converting to AD in the future3–5.